Document is current
Any future updates will be listed below
-
Authors
Lehnert, Thomas
Röver, Christian https://orcid.org/0000-0002-6911-698X
Köpke, Sascha https://orcid.org/0000-0003-4106-4919
Rio, Jordi https://orcid.org/0000-0003-4546-7627
Chard, Declan https://orcid.org/0000-0003-3076-2682
Fittipaldo, Andrea V. https://orcid.org/0000-0002-2832-9241
Friede, Tim https://orcid.org/0000-0001-5347-7441
Heesen, Christoph
Rahn, Anne C. https://orcid.org/0000-0002-9051-3621
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01KG1804)
Universität zu Lübeck
- License Information
-
More Information
Article History
Received: 7 December 2021
Accepted: 28 May 2022
First Online: 1 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: JR: has received honoraria for consultancy from Mylan, Novartis and Sanofi-Aventis and compensation for lectures and educational presentations from, Merck-Serono, Novartis, Teva and Sanofi-AventisDC: is a consultant for Biogen and Hoffmann-La Roche. In the last 3 years, he has received research funding from Hoffmann-La Roche, the International Progressive MS Alliance, the MS Society, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, and speaker’s honorarium from Novartis. He co-supervises a clinical fellowship at the National Hospital for Neurology and Neurosurgery, London, which is supported by Merck.MS: has received Grants (Roche, Novartis, Biogen), fees for educational events and lectures (Roche, Novartis, Biogen, Merck, Sanofi, Celgene), support for travelling and participation to meetings (Roche, Novartis, Biogen, Merck, Sanofi, Celgene) and payment for participation on a Data Safety Monitoring Board, Advisory Board, or Guideline Panel (Roche, Novartis, Biogen, Merck, Sanofi, Celgene, GeNeuro, Medday) and that they have been involved in conducting a study funded by Merck that is eligible for inclusion in the review.TF: has received within the past 3 years personal fees for participation in the Scientific Board and lectures of the JUMPstart programme from Fresenius Kabi, for participation in data monitoring committees from Novartis, Bayer, Janssen, Roche, Daiichi-Sankyo, Boehringer Ingelheim, Coherex Medical and BiosenseWebster and for statistical consultancies from Novartis, Bayer, CSL Behring, Galapagos, Vifor, Mediconomics, and Penumbra, but all outside the submitted work.CH: has received research grants from Roche, Merck, Bristol Myers Squibbs, Sanofi, honoraries for talks from Merck and a travel grant from Celgene. TL, CR, SK, AF and AR declare that they have no competing interests.
